CareDx Inc. (CDNA) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, CDNA scores 69 out of 100, a C+ grade, labeled "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:

• Fundamental Cash Engine (13 / 20): ROIC of -8.2% and an FCF yield of 0.67%. The cash-generation pillar is weak relative to capital employed, so the score rests on the company generating positive free cash flow rather than on earnings quality.
• Whale 13F Flow (17 / 20): Scored on institutional accumulation and options positioning. This is the strongest pillar, indicating that institutional positioning is a main support for the rating. The source data does not itemize specific holder positions.
• Insider Conviction (10 / 20): Based on SEC Form 4 and Congressional PTR cluster flow. This is the weakest pillar, suggesting insider activity provides limited conviction support. Underlying trade detail is not available in source data.
• Macro Regime Fit (13 / 20): Beta of 1.06 and sector sensitivity. The stock moves roughly in line with the market, so it offers little defensive cushion in a risk-off environment and little asymmetric upside from beta alone.
• Forensic Balance Sheet (16 / 20): Altman Z-Score of 19.22, Piotroski F-Score of 7/9, and Debt/Equity of 0.15. This is the second-strongest pillar and the main reason the balance sheet does not weigh the rating down.

For a prospective investor evaluating the stock today, the rating points to a balanced profile: a conservatively financed balance sheet and institutional support offset weak returns on capital, thin free-cash-flow yield, and limited insider conviction. The "Watch for Breakout" label implies the rating is conditional on improvement in cash generation or a shift in flow signals rather than on the current state. Valuation tradeoffs are visible in the market data: the stock trades at a forward P/E of 21 while trailing EPS is negative (-0.41), so the valuation depends on expected earnings recovery that the source data does not quantify.

CareDx Inc. is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry. The source data does not describe its products, customers, or revenue model. The profile identifies the company as operating in Medical Specialities with a market capitalization of $3.7B. Revenue of $379.8M for FY 2025 is reported in the SEC financials, but the source data does not specify how that revenue is generated or to whom it is sold.

Per the SEC financials, revenue grew from $280.3M in FY 2023 to $379.8M in FY 2025, but FY 2025 returned to an operating loss of $-30.8M after a positive operating income of $40.8M in FY 2024. Per the market data, the operating margin is -8.1%, the net margin is -5.6%, and ROIC is -8.2%. The forensic balance sheet pillar cites an Altman Z-Score of 19.22, a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 0.15. Debt fell from $476.2M in FY 2023 to $49.6M in FY 2025, and FY 2025 free cash flow was positive at $24.9M.

The news feed contains six items, all related to CDNA, published over roughly the prior 15 hours. Most are aggregator or generic stock-coverage pieces rather than company announcements:

• Market-wire coverage (YELLOW): Yahoo! Finance Canada, Yahoo Finance Singapore, and StockInvest.us pieces describe market action, institutional positioning, and fundamental catalysts in generic terms. The source data does not specify which catalysts these refer to.
• Catalyst items (GREEN): The Motley Fool piece is titled "Why CareDx Stock Soared Today," and a GuruFocus piece reports shares surging 4.8% alongside a GF Score of 64. The underlying drivers of these moves are not described in the source data.
• Simply Wall St (YELLOW): Carries a headline referencing a $74 target and a fair-value gap of roughly 30%. The source data does not provide the basis for that estimate, and it is not corroborated by the analyst data section.

Risk watch items: The price-to-52-week-high gap is wide, with the range running from $14.27 to $90.87 and the current price at $71.52. The news wire does not identify the cause of the swings.

Proprietary signals: None are present in the Butterfly graph.

• What products and services generate the $379.8M in FY 2025 revenue, and who are the primary customers?
• What drove the swing from a $40.8M operating profit in FY 2024 to a $-30.8M operating loss in FY 2025, and is the cause one-time or structural?
• What specific events are behind the "soared" and 4.8% surge headlines, and are they company-driven or market-driven?
• Who are the institutional holders and insiders behind the Whale and Insider pillar scores, and what are the sizes and timing of their positions?
• What is the basis for the $74 target and fair-value estimate cited in the news feed, and why is trailing P/E unavailable?